{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:41Z","timestamp":1787163401660,"version":"build-2736575974"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The myelodysplastic syndromes (MDS) are characterized by cytopenias and risk of transformation to acute myeloid leukemia (AML). Although new treatments are available, a mainstay in MDS remains supportive care, which aims to minimize the impact of cytopenias and transfusion of blood products. Red blood cell (RBC) transfusions place patients at risk of iron overload (IOL). In beta-thalassemia major (BTM), IOL from chronic RBC transfusions inevitably leads to organ dysfunction and death. With iron chelation therapy (ICT), survival in BTM improved from the second decade to near normal and correlated with ICT compliance. Effects of ICT in BTM include reversal of cardiac arrhythmias, improvement in left ventricular ejection fraction, arrest of hepatic fibrosis, and reduction of glucose intolerance.<\/jats:p>\n                  <jats:p>It is not clear whether these specific outcomes are applicable to MDS. Although retrospective, recent studies in MDS suggest an adverse effect of transfusion dependence and IOL on survival and AML transformation, and that lowering iron minimizes this impact. These data raise important points that warrant further study. ICT is potentially toxic and cumbersome, is costly, and in MDS patients should be initiated only after weighing potential risks against benefits until further data are available to better justify its use. Since most MDS patients eventually require RBC transfusions, the public health implications both of transfusion dependence and ICT in MDS are considerable. This paper summarizes the impact of cytopenias in MDS and treatment approaches to minimize their impact, with a focus on RBC transfusions and their complications, particularly with respect to iron overload.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.664","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T15:35:31Z","timestamp":1260545731000},"page":"664-672","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?"],"prefix":"10.1182","volume":"2009","author":[{"given":"Heather A.","family":"Leitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Vickars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111705145440600_R1","doi-asserted-by":"crossref","unstructured":"Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u20132088.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"2019111705145440600_R2","doi-asserted-by":"crossref","unstructured":"Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503\u20133510.","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"2019111705145440600_R3","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Fu AZ, Maciejewski JP, Golshayan AR, Kalaycio ME, Kattan MW. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer. 2007;109:1125\u20131132.","DOI":"10.1002\/cncr.22497"},{"key":"2019111705145440600_R4","doi-asserted-by":"crossref","unstructured":"Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u2013425.","DOI":"10.1182\/blood-2005-10-4149"},{"key":"2019111705145440600_R5","doi-asserted-by":"crossref","unstructured":"Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239\u2013252.","DOI":"10.1046\/j.1365-2141.2001.03195.x"},{"key":"2019111705145440600_R6","doi-asserted-by":"crossref","unstructured":"Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594\u20137603.","DOI":"10.1200\/JCO.2005.01.7038"},{"key":"2019111705145440600_R7","doi-asserted-by":"crossref","unstructured":"Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol. 2008;83:611\u2013613.","DOI":"10.1002\/ajh.21192"},{"key":"2019111705145440600_R8","doi-asserted-by":"crossref","unstructured":"Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)\/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol. 2008;83:765\u2013770.","DOI":"10.1002\/ajh.21249"},{"key":"2019111705145440600_R9","unstructured":"Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588\u20131590."},{"key":"2019111705145440600_R10","doi-asserted-by":"crossref","unstructured":"Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood. 2008;112:238\u2013239.","DOI":"10.1182\/blood.V112.11.640.640"},{"key":"2019111705145440600_R11","doi-asserted-by":"crossref","unstructured":"Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs. Blood. 2008;112:45\u201352.","DOI":"10.1182\/blood-2008-01-134858"},{"key":"2019111705145440600_R12","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw. 2008;6:942\u2013953.","DOI":"10.6004\/jnccn.2008.0072"},{"key":"2019111705145440600_R13","doi-asserted-by":"crossref","unstructured":"Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574\u2013578.","DOI":"10.1056\/NEJM199409013310903"},{"key":"2019111705145440600_R14","doi-asserted-by":"crossref","unstructured":"Leitch HA, Goodman TA, Wong KK, Vickars LM, Galbraith PF, Leger CS. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy [abstract]. Blood. 2006;108:78.","DOI":"10.1182\/blood.V108.11.249.249"},{"key":"2019111705145440600_R15","unstructured":"Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. a prospective analysis by the GFM [abstract]. Blood. 2007;110:80\u201381."},{"key":"2019111705145440600_R16","doi-asserted-by":"crossref","unstructured":"Leitch HA, Leger CS, Goodman TA, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk. 2008;2:205\u2013211.","DOI":"10.3816\/CLK.2008.n.026"},{"key":"2019111705145440600_R17","doi-asserted-by":"crossref","unstructured":"Greenberg P, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6:902\u2013926.","DOI":"10.6004\/jnccn.2008.0069"},{"key":"2019111705145440600_R18","doi-asserted-by":"crossref","unstructured":"Palmer SR, Tefferi A, Hanson CA, Steensma DP. Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. Br J Haematol. 2008;140:722\u2013725.","DOI":"10.1111\/j.1365-2141.2008.07006.x"},{"key":"2019111705145440600_R19","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109:1705\u20131714.","DOI":"10.1002\/cncr.22602"},{"key":"2019111705145440600_R20","doi-asserted-by":"crossref","unstructured":"Oliva EN, Dimitrov BD, Benedetto F, D\u2019Angelo A, Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res. 2005;29:1217\u20131219.","DOI":"10.1016\/j.leukres.2005.03.004"},{"key":"2019111705145440600_R21","doi-asserted-by":"crossref","unstructured":"Goldberg SL, Mody-Patel N, Warnock N. Prevalence of cardiac disease among a US Medicare population with myelodysplastic syndromes. Leuk Res. 2007;31:S103.","DOI":"10.1016\/S0145-2126(07)70187-X"},{"key":"2019111705145440600_R22","doi-asserted-by":"crossref","unstructured":"Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23:953\u2013959.","DOI":"10.1016\/S0145-2126(99)00113-7"},{"key":"2019111705145440600_R23","unstructured":"Denton TA, Diamond GA, Matloff JM, Gray RJ. Anemia therapy: individual benefit and societal cost. Semin Oncol. 1994;21:29\u201335."},{"key":"2019111705145440600_R24","doi-asserted-by":"crossref","unstructured":"Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004;104:321\u2013327.","DOI":"10.1182\/blood-2003-07-2252"},{"key":"2019111705145440600_R25","doi-asserted-by":"crossref","unstructured":"Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008:166\u2013175.","DOI":"10.1182\/asheducation-2008.1.166"},{"key":"2019111705145440600_R26","doi-asserted-by":"crossref","unstructured":"Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26\u201336.","DOI":"10.1159\/000203853"},{"key":"2019111705145440600_R27","unstructured":"Hartmann J, Sinzig U, Wulf G, et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS [abstract]. Blood. 2008;11:932."},{"key":"2019111705145440600_R28","doi-asserted-by":"crossref","unstructured":"Yuan J, Lovejoy DB, Richardson DR. Novel di-2- pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004;104:1450\u20131458.","DOI":"10.1182\/blood-2004-03-0868"},{"key":"2019111705145440600_R29","doi-asserted-by":"crossref","unstructured":"Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004;104:2967\u20132975.","DOI":"10.1182\/blood-2004-05-1866"},{"key":"2019111705145440600_R30","doi-asserted-by":"crossref","unstructured":"Jiang Y, Xue ZH, Shen WZ, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT\/enhancer-binding protein-alpha. Leukemia. 2005;19:1239\u20131247.","DOI":"10.1038\/sj.leu.2403734"},{"key":"2019111705145440600_R31","doi-asserted-by":"crossref","unstructured":"Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007;42:830\u2013836.","DOI":"10.1007\/s00535-007-2095-z"},{"key":"2019111705145440600_R32","doi-asserted-by":"crossref","unstructured":"Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008;100:996\u20131002.","DOI":"10.1093\/jnci\/djn209"},{"key":"2019111705145440600_R33","doi-asserted-by":"crossref","unstructured":"Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007;138:587\u2013593.","DOI":"10.1111\/j.1365-2141.2007.06695.x"},{"key":"2019111705145440600_R34","doi-asserted-by":"crossref","unstructured":"Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity\/mortality. Eur J Haematol. 2007;78:487\u2013494.","DOI":"10.1111\/j.1600-0609.2007.00842.x"},{"key":"2019111705145440600_R35","doi-asserted-by":"crossref","unstructured":"Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009;25:139\u2013147.","DOI":"10.1185\/03007990802565867"},{"key":"2019111705145440600_R36","unstructured":"Leitch HA, Badawi MA, Chase J, Vickars LM. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome: a case report and review of the literature [abstract]. Haematologica. 2009;94:539."},{"key":"2019111705145440600_R37","unstructured":"List AF, Baer MR, Steensma D, et al. Deferasirox (ICL670); Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood. 2008;112:523."},{"key":"2019111705145440600_R38","doi-asserted-by":"crossref","unstructured":"Rachmilewitz E, Merkel D, Ghoti H, et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox [abstract]. Blood. 2008;112:924\u2013925.","DOI":"10.1182\/blood.V112.11.2675.2675"},{"key":"2019111705145440600_R39","doi-asserted-by":"crossref","unstructured":"Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83:858\u2013861.","DOI":"10.1002\/ajh.21269"},{"key":"2019111705145440600_R40","doi-asserted-by":"crossref","unstructured":"Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk Res. 2009;33:1158\u20131163.","DOI":"10.1016\/j.leukres.2008.10.017"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/664\/645540\/664_672ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/664\/645540\/664_672ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T02:21:58Z","timestamp":1590286918000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/664\/19848\/Supportive-care-and-chelation-therapy-in-MDS-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.664","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}